Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Poolbeg Pharma PLC reports a robust first half of 2024, with its lead candidate POLB 001 showing promise in cancer immunotherapy-induced CRS and a potential US$10 billion market opportunity. The company has strengthened its patent portfolio, maintained a strong cash balance, and engaged in strategic partnerships, including an option agreement for a promising treatment for Behçet’s Disease. With a focus on rare and orphan diseases, Poolbeg’s experienced leadership team is driving the company’s development and commercialization efforts.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.
